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Introduction
The role of androgens in breast cancer etiology has been
a subject of both curiosity and confusion. It is still unclear
by which mechanisms testosterone exerts its activity in
the female breast, and whether the effects are predomi-
nantly proliferative or anti-proliferative on breast cells at
physiologic levels. In the present review we evaluate the
results from epidemiologic studies on the role of circulat-
ing testosterone and a functional polymorphism in the
androgen receptor (AR) in breast cancer. We also high-
light some of the epidemiologic challenges in addressing
these questions.
Sources of endogenous testosterone
There are two main sources of androgens in women.
Testosterone is produced directly by the ovary and by
conversion of the adrenal androgens dehydroepiandro-
sterone and dehydroepiandrosterone-sulfate into andro-
stenedione, and then further to testosterone in peripheral
tissue [1]. In premenopausal women, approximately 25%
of circulating testosterone is secreted directly from the
adrenal gland and 25% from the ovary, whereas the
remaining 50% is produced by peripheral conversion of
androstenedione [2]. Testosterone levels vary over the
menstrual cycle with peak levels mid-cycle, and diurnally
with highest levels in the early morning [3].
Testosterone and androstenedione are produced by the
interstitial cells of the ovarian stroma and may continue to
respond to gonadotopins and produce testosterone after
the menopause [4]. In normal postmenopausal women the
ovarian vein has been observed to have higher concentra-
tions of testosterone than is found in peripheral blood;
bilateral oophorectomy results in reductions in testos-
terone levels by as much as 50% [5].
Several smaller cross-sectional studies have found lower
testosterone levels in postmenopausal than premenopausal
women [6–8] or lower levels in perimenopausal than pre-
menopausal women [2]. Large longitudinal studies that have
followed women through the menopausal transition have
observed either no significant change in testosterone [2,9]
or a 15% decrease in both testosterone and androstene-
dione at menopause [10]. In one study of women aged
50–89 years testosterone levels were lowest at the time of
the menopause, whereas women older than 70 years or
more than 20 years postmenopause had levels approximat-
ing those of premenopausal women [11].
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In summary, there is increasing evidence that the ovary
continues to produce androstenedione and testosterone
in healthy postmenopausal women. Levels may either
remain the same or decrease slightly at menopause.
However, women with bilateral oophorectomy may be
androgen deficient.
Testosterone and breast cancer risk
Prospective studies that examined the association
between testosterone and breast cancer
Data from eight prospective cohort studies have been
reported on the association between endogenous testos-
terone levels and breast cancer risk using testosterone
measured from blood samples gathered at baseline from
postmenopausal women [12–19]. Six of these studies
were nested case–control studies [12,14–18]; one was a
case–cohort study [19] and one a full cohort study [13].
Only one of these studies reported results for pre-
menopausal women [12].
Six of the eight studies reported a statistically significant
increase in postmenopausal breast cancer risk with
increasing levels of endogenous testosterone [14–19]. A
recently conducted pooled analysis [20] of these eight
prospective studies estimated that the relative risk for
breast cancer in women whose levels of testosterone were
in the top quintile as compared with women in the bottom
quintile was 2.22 (95% confidence interval 1.59–3.10). A
statistically significant dose–response relationship was
also observed (P for trend <0.001) [20]. Two of the
studies also reported statistically significantly increasing
breast cancer risk with increasing levels of free testos-
terone [15,19], a measure of bioavailable testosterone.
The study of premenopausal women [12] found no statisti-
cally significant differences between cases and noncases
in mean levels in either premenopausal or postmenopausal
women, but the sample size was small (premenopausal
women: 17 cases, 67 controls; postmenopausal women:
22 cases, 88 controls).
Can the observed association between testosterone
levels and breast cancer risk be due to bias?
Effects of measurement biases
One limitation of the studies reviewed is that serum
testosterone may not be the ideal measure of testos-
terone. Total testosterone includes both free testosterone
and bound testosterone. Furthermore, serum levels do not
take into account the peripheral conversion of precursor
androgens into testosterone in the breast tissue itself. The
effect of this measurement error is most likely to be nondif-
ferential, therefore biasing results toward the null.
Measurement biases due to use of a single hormone mea-
surement or degradation of hormones in stored speci-
mens over time would most likely be nondifferential,
resulting in attenuated estimates of disease risk. All of the
existing prospective studies (Table 1) analyzed testos-
terone measured from only one blood draw, which might
not be representative of the cumulative exposure to
testosterone; however, given the prospective design of
the studies, any inaccuracy in measurement would proba-
bly bias risk estimates toward the null.
The consideration of time of day that blood was drawn
and fasting status can help to avoid the biases due to
using a single hormone measurement. To avoid this bias,
three of the studies either matched with respect to time of
blood draw [14,18] or restricted individuals to having their
blood drawn in the morning [13]. Because the effect of
these sporadic variations would be to bias the results
toward the null, this may help to explain one of the null
associations observed [12].
The studies that observed an association between testos-
terone and breast cancer risk attempted to reduce mea-
surement bias due to degradation by matching cases to
controls on the date of blood draw [14–18] and storage
conditions such as sample location/shelf in the freezer
[15]. This was not done in the studies reporting no associ-
ation between testosterone and breast cancer risk [12,13]
or in one of the positive studies [19].
Laboratory assay variation would also most likely be non-
differential because cases and controls were analyzed
concurrently in these studies. The intra-assay and inter-
assay coefficients of variation in these studies were
rather good, ranging from 4% to 14%. However, the
coefficient of variation was not reported in one of the null
studies [12].
Thus, although there may be some attenuation in effect esti-
mates in all of the studies, it is not clear whether measure-
ment bias due to degradation can explain the discrepancies
between the two null studies and the positive studies.
Temporal Bias
If breast cancer development increases testosterone
levels, then studies that included individuals diagnosed
shortly after baseline hormone measurement may have
artificially elevated estimates of the risk for breast
cancer associated with testosterone levels. Two of the
positive studies and both of the null studies excluded
those who were diagnosed 6–24 months after baseline
[12–14,17]. However, the study with the most conserv-
ative cut-point of 24 months [14] reported a significant
positive association between testosterone levels and
breast cancer risk. Thus, although it is possible that
temporal bias played a role in the four positive studies
with no exclusions, this latter study suggests that tem-
poral bias cannot explain the association between
testosterone and breast cancer risk.166
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Effects of confounding
Lack of control for body mass index (BMI) or age at
menopause could result in a positive bias away from the
null. All of the studies that reported a significant associa-
tion between testosterone levels and breast cancer risk
included either BMI or height and weight as covariates in
the statistical model. All but one of the null studies [13]
considered either the amount of time menopausal
[12,14,16] or age at menopause [15,17–19] as a covari-
ate to control for the effects of menopause on testos-
terone levels. Thus, it is unlikely that confounding by these
variables can explain the associations observed between
testosterone levels and breast cancer risk.
Comparability/generalizability
All of the prospective studies that examined the testos-
terone–breast cancer association were conducted using
cohorts from Caucasian populations. Only two studies
[15,16] were conducted outside the USA, one in Italy [15]
and one on the island of Guernsey [16]. It is therefore
unlikely that differences in the populations studied can
explain the discrepant results between studies. There are,
as far as we know, no prospective data from nonwhite
populations.
Studies of testosterone measured after diagnosis that
examined the testosterone–breast cancer association
Several case–control studies published during the past
20 years have evaluated the association between testos-
terone levels and breast cancer risk. Comparisons with
levels in control individuals have shown that breast cancer
patients who were postmenopausal [21–25] and those
who were premenopausal [26–28] had significantly ele-
vated testosterone levels. Table 2 presents the odds ratios
of breast cancer associated with categories of serum
testosterone, whereas Table 3 presents results of studies
that compared mean levels of testosterone. The measures
of testosterone in cases were almost twice those of con-
trols. Although these retrospective studies support the
prospective study results showing an association between
increased testosterone and increased breast cancer risk,
these results may not be as readily interpretable as those
from the prospective studies, given the possibility that the
presence of cancer, or the treatment for it, might have
increased testosterone levels.
Summary
Both retrospective and prospective studies have reported
statistically significant associations between increased
levels of testosterone and increased breast cancer risk.
These associations are unlikely to be due to measurement
biases, the influence of disease, or lack of adjustment for
the confounding effects of BMI or age at menopause.
Available online http://breast-cancer-research.com/content/5/3/164
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Table 3
Mean levels of testosterone in breast cancer cases and controls
Author, year
[reference] Population Exposure Group n Mean1 SD P2
Secreto, Postmenopausal Serum T Controls 30 310 110
1983 [21] women Carcinoma 28 550 200 0.001
Secreto, Premenopausal Urinary T Controls 22 6.25 3.48
1983 [26] women Familiality 21 5.41 3.60 NS
Hyperplasia 39 6.97 4.44 NS
Carcinoma 18 11.3 6.78 0.01
Secreto, Premenopausal Serum T Controls 55 470 160
1984 [27] women Breast Hyperplasia 31 550 200 <0.05
Breast Cancer 23 620 220 <0.005
Hill, Postmenopausal Serum T Healthy Caucasian 43 NS
1985 [22] women Healthy Japanese 59 NS 0.01
Cases Japanese 33 NS3 0.01
Adlercreutz, Postmenopausal Serum T Vegetarians 10 172.80 86.40
1989 [23] women Omnivores 9 233.28 66.24 <0.05
Cases 8 319.68 132.48 <0.05
1Serum T converted to pg/ml and urinary T converted to µg/24 hours. 2Comparisons with mean levels in controls using the t-test. 3Comparison
with healthy Japanese group. SD, standard deviation; T, testosterone.
Table 2
The relative risk of breast cancer associated with testosterone levels: results from case–control studies
Author, year
[reference] Population Exposure Cases Controls Categories1 OR 95% CI P
Secreto, Premenopausal Serum T 13 47 <590 1.0
1984 [27]2 women in Milan 4 9 590–670 2.6 0.6–10.9
10 6 671+ 10.2 2.6–40.0 0.0004
Urinary T 9 35 <8.2 1.0
4 7 8.2–10.5 2.3 1.2–12.9
10 5 10.6+ 8.4 2.1–33.6 0.002
Secreto, Women in Milan Serum T 31 51 <309 1.0
1989 [28]2 age 30–49 years 32 17 309+ 3.4 1.6–7.3 0.05
Urinary T 36 50 <7.6 1.0
24 16 7.6+ 2.1 0.9–4.8 NS
Secreto, Postmenopausal Serum T 16 40 <146 1.0
1991 [24]3 women in Milan 16 40 146–212 1.2 0.5–3.0
<69 years of age 18 38 213–275 1.5 0.6–3.7
25 32 >275 2.7 1.1–6.7 0.03
Urinary T4 11 43 <18 1.0
14 38 18–31 1.2 0.5–2.9
17 37 32–46 2.2 0.8–5.7
30 26 >46 4.7 1.8–12.1 0.001
Serum DHT 15 37 <36 1.0
20 40 36–57 1.6 0.7–3.7
16 38 58–82 1.3 0.5–3.1
24 35 >82 2.0 0.8–5.0 NS
Lipworth, Postmenopausal Serum T6 23 35 260 1.00
1996 [25]5 women from Sweden 15 27 350 0.75 0.33–1.75
47 30 470 2.64 1.27–5.46
36 30 700 2.30 0.97–5.50 0.041
1Serum T and DHT converted to pg/ml and urinary T converted to µg/24 hours. 2Age adjusted model. 3Adjusted for age, occupation and number of
children. 4Units in pg/ml. 5Adjusted for age and residence. 6Categorized by quartile medians. CI, confidence interval; DHT, dihydrotestosterone;
NS, not significant; OR, odds ratio; T, testosterone.169
Androgen receptor, the AR-CAG repeat, and
breast cancer risk
The main receptor for testosterone is the AR. A functional
polymorphism in the AR gene has been examined in
female breast cancer, and the literature is reviewed to
shed light on the possible mechanisms by which testos-
terone may affect breast cancer risk.
Androgen receptor protein and breast cancer
The AR is expressed in the majority of breast cancers
[29–35]. Several studies have been conducted to
examine the effects of androgens on the growth of
AR-positive breast cancer cell lines. These studies have
reported both inhibitory [36,37] and stimulatory [38,39]
effects. These divergent effects have been observed to be
specific to the cell line under study [40].
To our knowledge, the only in vivo study of the effect of
testosterone on breast cell proliferation was conducted in
rats and showed that treatment with testosterone results
in both tumor regression and a reduction in estrogen
receptor expression [41]. However, it is unclear whether
the testosterone levels used represent physiologic doses.
No in vivo or epidemiologic studies have examined the
association between serum or tissue testosterone levels
and breast cell proliferation in tumors with varying degrees
of AR expression.
In summary, the effects of androgens on breast cancer
cell growth are still unclear. In contrast to the epidemio-
logic observation of a consistent association between
serum testosterone levels and increasing breast cancer
risk, in vivo studies reported an antiproliferative effect and
in vitro studies reported both proliferative and antiprolifera-
tive effects.
The androgen receptor gene and a polymorphic CAG
repeat
The AR is encoded by a single 90 kilobase gene on the
X chromosome (Xq11-q12), which encodes a 11-kilobase
mRNA transcript composed of eight exons [42–46]. Epi-
demiologic evidence for a role of the AR gene in breast
cancer was first suggested by studies of male breast cancer
patients. A mutation in AR in the DNA-binding domain result-
ing in an inability to bind androgens was first reported in a
pair of brothers with breast cancer [47]. In a study of
13 male breast cancer patients, one was observed to carry a
similar mutation [48]. In another small study of 11 male
breast cancer patients [49], this mutation was not observed.
These results suggested that the mutation may play a role in
the development of breast cancer in some males.
Within the first exon of AR lies a polymorphic CAG repeat
that encodes a polyglutamine tract of variable length. The
normal size range of these repeats is between 6 and
39 repeats [50,51]. Between 40 and 66 repeats have
been observed in patients with a rare, neurodegenerative
disorder called spinal and bulbar muscular atrophy [52],
which is characterized by androgen insensitivity with
gynecomastia, testicular atrophy, oligospermia, azoosper-
mia, and elevated serum gonadotropins.
AR-CAG repeat length and androgen receptor activity
Several studies have observed an association between
increasing AR-CAG repeat length and a linear decrease in
AR transactivation activity [53–56]. Consistent with this,
male carriers of the short AR-CAG repeat length are at
increased risk for prostate cancer [51,57–62].
AR-CAG repeat length and breast cancer
The association between the length of the AR-CAG
repeat polymorphism and breast cancer risk has been
examined in several case–control studies (Table 4)
[63–68]. The long AR-CAG repeat, which is representa-
tive of the less active AR, was associated with a statisti-
cally significant increase in breast cancer risk in a
population of women from Quebec [66] and in a popula-
tion of BRCA1 mutation carriers [63]. Four additional
studies [64,65,67,69] reported slightly increased risk for
breast cancer associated with the long allele, but none of
these findings were statistically significant. A study nested
within the Nurses’ Health Study cohort [68] found no
increased breast cancer risk associated with the long AR
allele overall, but an increased risk was observed when
analyses were limited to those individuals with a first-
degree family history of breast cancer (odds ratio 1.70,
95% confidence interval 1.2–2.4). Another trinucleotide
repeat in the AR, a GGC repeat, has been observed to be
associated with prostate cancer risk [59,60,62,70,71].
One of three studies that examined the GGC repeat
length and breast cancer [65,67,69] found a significant
association in women diagnosed before age 45 years
[69], but no evidence of an interaction between the CAG
and GGC repeat with breast cancer risk was observed.
The three studies that reported a significant association
between long AR-CAG repeat and breast cancer risk
[63,66,68] included both premenopausal and post-
menopausal women. One study stratified with respect to
menopausal status and found that the significant associa-
tion with the long AR-CAG repeat was observed only in
postmenopausal women (odds ratio 3.22, 95% confi-
dence interval 1.54–6.75) and not in premenopausal
women (odds ratio 1.03, 95% confidence interval
0.43–2.48). If this effect modification is true then it may
explain, at least in part, the nonsignificant results in the
studies restricted to women aged under 40 years [64].
Issues with the studies of AR-CAG repeat length and
breast cancer risk
The gene for the AR lies on the X chromosome, and there-
fore women carry two alleles whereas men carry only a
Available online http://breast-cancer-research.com/content/5/3/164170
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single allele. In general, normal women are a mosaic, with
one allele randomly expressed in each cell. A recent study
[72] reported that 13% of young (27–45 years old) breast
cancer cases exhibited preferential activation of one of the
AR alleles as measured by genotyping of peripheral blood
DNA, but there was no preference toward the allele with
the longer or shorter CAG repeat. Analyses of the AR in
women that only consider the length of the CAG repeat
on one allele assume that this is the active allele in the
breast tissue. Analyses that use the average of the CAG
repeat lengths or the sum of the repeats consider the con-
tributions of both alleles; however, if only one allele is pref-
erentially expressed then this would result in
misclassification. There is a high rate of heterozygosity in
the AR-CAG repeat length, and therefore this is likely to
be a major misclassification problem, which should bias
the results toward the null. Genotyping methods can be
optimized to detect better whether there is a preferentially
active  AR allele by either genotyping tumor tissue or
serum DNA using methylation sensitive enzymes [72].
Summary
The studies conducted thus far suggest that the long
AR-CAG repeat (less active AR) may be associated with
increased breast cancer risk in women who are post-
menopausal, have a first-degree family history of breast
cancer or who have a known BRCA1 mutation. The location
of the AR gene on the X chromosome means that results
from epidemiologic studies will be biased toward the null as
long as we do not know which allele is expressed.
Discussion
If the long AR-CAG repeat (less active AR) is associated
with increased breast cancer risk in postmenopausal
women, then how do these results coincide with results
showing that increased testosterone levels increase post-
menopausal breast cancer risk?
One hypothesis to explain this apparent paradox is that
the less active AR may be involved in a physiologic feed-
back associated with increased circulating testosterone.
However, the only data available discount this hypothesis.
Two studies have examined the association between the
AR-CAG repeat length and circulating testosterone levels
in normal women [68,73]. AR-CAG repeat length was
inversely associated with testosterone levels. In other
words, the less active AR was associated with lower cir-
culating testosterone levels, and the results were statisti-
cally significant both in a study of premenopausal women
[73] and in a study of postmenopausal women [68].
If the AR is not involved in a feedback mechanism to influ-
ence testosterone levels in postmenopausal women, then
it is possible that the effect of testosterone on the breast
epithelium does not act through binding to the AR. Testos-
terone may exert its effect on breast tissue through con-
version of testosterone to estrone, which is then aroma-
tized into estradiol in adipose tissue, and the increased
estradiol levels may result in increased breast cell prolifer-
ation and breast cancer risk.
Testosterone may also exert an indirect effect on breast
cancer proliferation by sequestering sex hormone binding
globulin, leaving more estradiol in the non-protein-bound
state and able to act on breast tissue [25,74]. Approxi-
mately 66% of total testosterone is bound to sex hormone
binding globulin, 31% is bound to albumin, and 2% is
bound to cortisol binding protein [75]. Two of the studies
suggesting an association between testosterone and
breast cancer [16,17] reported that this association disap-
peared when adjusting for estradiol levels. However, in the
pooled analysis [20] the significant association between
testosterone and breast cancer risk remained after adjust-
ment for estradiol [20].
Finally, it is possible that further studies will show that
AR-CAG repeat length is not linked to breast cancer risk.
Conclusion
Prospectively conducted epidemiologic studies have
found that increased levels of serum testosterone are
associated with an increase in postmenopausal breast
cancer risk. However, a number of questions remain.
Several lines of evidence suggest a role of AR in breast
cancer risk, and sparse epidemiologic data suggest that a
long  AR-CAG repeat yielding a less active AR may be
associated with increased risk. There still remain a number
of questions on how testosterone increases breast cancer
risk. Although in vitro studies report both proliferative and
antiproliferative effects of testosterone on the growth of
various breast cancer cell lines, we still need to further
understand under which in vivo circumstances does
testosterone exert these effects. Finally, we do not know
whether androgens affect breast cancer risk in pre-
menopausal women. Further analyses of the role of
AR-CAG repeat length and breast cancer using genotyp-
ing methods that assess which allele is the active AR allele
are clearly needed. Additional data are also needed to help
elucidate the apparent paradox between the AR-CAG
repeat length, testosterone levels, and breast cancer risk.
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